Wall Street brokerages expect The Joint Corp. (NASDAQ:JYNT – Get Rating) to announce sales of $22.88 million for the current quarter, Zacks reports. Two analysts have issued estimates for Joint’s earnings. The highest sales estimate is $23.00 million and the lowest is $22.76 million. Joint posted sales of $17.55 million in the same quarter last year, which suggests a positive year over year growth rate of 30.4%. The company is scheduled to report its next quarterly earnings results after the market closes on Monday, January 1st.
According to Zacks, analysts expect that Joint will report full year sales of $103.20 million for the current fiscal year, with estimates ranging from $100.91 million to $105.50 million. For the next financial year, analysts anticipate that the business will post sales of $128.93 million, with estimates ranging from $123.76 million to $134.10 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Joint.
Joint (NASDAQ:JYNT – Get Rating) last issued its quarterly earnings results on Thursday, February 24th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.07). The business had revenue of $22.43 million during the quarter, compared to analyst estimates of $22.21 million. Joint had a net margin of 8.82% and a return on equity of 26.30%. During the same period in the prior year, the business posted $0.12 earnings per share.
JYNT stock opened at $30.52 on Friday. Joint has a twelve month low of $29.84 and a twelve month high of $111.06. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 0.07. The company has a market cap of $441.32 million, a PE ratio of 63.58 and a beta of 1.27. The business’s 50-day simple moving average is $35.56 and its 200 day simple moving average is $57.59.
In related news, CEO Peter D. Holt acquired 1,500 shares of the company’s stock in a transaction on Wednesday, March 16th. The stock was purchased at an average cost of $33.24 per share, for a total transaction of $49,860.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Jake Singleton bought 1,515 shares of the stock in a transaction dated Wednesday, March 16th. The stock was acquired at an average price of $33.00 per share, with a total value of $49,995.00. The disclosure for this purchase can be found here. Corporate insiders own 6.10% of the company’s stock.
Several large investors have recently made changes to their positions in JYNT. Captrust Financial Advisors increased its stake in shares of Joint by 117.6% in the third quarter. Captrust Financial Advisors now owns 285 shares of the company’s stock valued at $28,000 after buying an additional 154 shares in the last quarter. Pinebridge Investments L.P. acquired a new stake in shares of Joint in the fourth quarter valued at $33,000. Point72 Hong Kong Ltd acquired a new stake in shares of Joint in the fourth quarter valued at $36,000. Marshall Wace North America L.P. acquired a new stake in shares of Joint in the first quarter valued at $47,000. Finally, USA Financial Portformulas Corp acquired a new stake in shares of Joint in the third quarter valued at $59,000. Institutional investors own 86.71% of the company’s stock.
Joint Company Profile (Get Rating)
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States.
- Get a free copy of the StockNews.com research report on Joint (JYNT)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.